<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01306825</url>
  </required_header>
  <id_info>
    <org_study_id>4683</org_study_id>
    <nct_id>NCT01306825</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Daptomycin Bone Penetration</brief_title>
  <acronym>DAPTO-HUS</acronym>
  <official_title>Clinical Evaluation of Daptomycin Bone Penetration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bone and joint infections are commonly due to Gram-positive bacteria. Treatment of these
      infections is difficult because of the need of prolonged duration of antimicrobial agents in
      combination with surgical procedure. Moreover, in recent years, a growing resistance pattern
      to various antimicrobial agents has been observed for Gram-positive bacteria. Consequently,
      there is an urgent need for new drugs with high bone penetration for the treatment of those
      infections. The investigators hypothesized that daptomycin allow to achieve high
      concentrations in bone compartments.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patients' percentage of which the intra-osseous daptomycin concentration is ≥ 8 times MIC (if available) or ≥ 8 times critical concentration (if Bacteriological documentation is unavailable)</measure>
    <time_frame>5 min before started administration of daptomycin, 5 min after administration of daptomycin and at random after perfusion of daptomycin</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Bone and Joint Infections</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient under treatment with daptomycin and undergoing imperative surgery with bone
        withdrawal
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patient under treatment with daptomycin for more than 3 days with dosage at 6 mg/kg

          -  Patient undergoing imperative surgery with bone withdrawal

          -  Signed, and dated informed consent as defined by the Institutional Review Board

          -  Male and female patients older than 18 years of age

          -  Patients with social insurance

          -  Patient with information on previous mandatory medical examination

        Exclusion criteria :

          -  Patient with no treatment by daptomycin or with a dosage &lt; 6mg/kg or with less than 3
             doses of daptomycine

          -  Patient with no need for surgery

          -  Patient younger than 18 years of age

          -  Pregnant and nursing women

          -  Patient refusal for inclusion

          -  Patients with deprived liberty

          -  Inability to complete the informed consent process because of problems with mental
             capacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Lefebvre, MD</last_name>
    <role>Study Director</role>
    <affiliation>Service des maladies infectieuses et tropicales - Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas Lefebvre, MD</last_name>
    <phone>33 3 69 55 05 45</phone>
    <email>nicolas.lefebvre@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service d'Orthopédie - Hôpital Centre de Chirurgie Orthopédie et de la Main (CCOM) - Hôpitaux Universitaires de Strasbourg - 10 av Achille Baumann -</name>
      <address>
        <city>Illkirch-Graffenstaden</city>
        <zip>67400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannot GAUDIAS, MD</last_name>
      <phone>33 3 88 55 23 45</phone>
      <email>jeannot.gaudias@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Jeannot GAUDIAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cyril BOERI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Plateau Technique de Microbiologie - Hôpitaux Universitaires de Strasbourg - 1, rue Koeberlé</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JEHL François, PHARM D</last_name>
      <phone>33 3 68 85 37 81</phone>
      <email>francois.jehl@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>François JEHL, PARM D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des maladies infectieuses et tropicales - Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Lefebvre, MD</last_name>
      <phone>33 3 69 55 05 45</phone>
      <email>nicolas.lefebvre@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas Lefebvre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel CHRISTMANN Daniel, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves HANSMANN, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2011</study_first_submitted>
  <study_first_submitted_qc>March 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2011</study_first_posted>
  <last_update_submitted>June 17, 2015</last_update_submitted>
  <last_update_submitted_qc>June 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Daptomycin</keyword>
  <keyword>Bone disease,infectious</keyword>
  <keyword>Osteomyelitis</keyword>
  <keyword>Diabetic foot</keyword>
  <keyword>Staphylococcus aureus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daptomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

